PreMD faces AMEX delisting
This article was originally published in The Gray Sheet
Executive Summary
Three days after firm announces FDA upheld a January 2008 decision that its PreVu skin cholesterol test is not substantially equivalent to standard-of-care blood cholesterol tests, PreMD says the American Stock Exchange plans to suspend trading in PreMD stock effective Aug. 28 and begin delisting proceedings. PreMD received an earlier notice in May of AMEX's intention to delist the company, but ultimately lost an appeal this month